Cancer.Net Associate Editor: Genitourinary (GU) Cancers
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Brian I. Rini, MD is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. A staff member of the Department of Solid Tumor Oncology of the Taussig Cancer Institute, Dr. Rini’s work focuses on genitourinary malignancies.
Dr. Rini earned his medical degree at the Ohio State University College of Medicine in Columbus, Ohio. After completing a residency program in internal medicine at University of Chicago Hospitals in Illinois, Dr. Rini was awarded a fellowship in hematology and oncology at the University of Chicago. Dr. Rini was an Assistant Professor at the University of California San Francisco before moving to Cleveland Clinic.
At Cleveland Clinic, Dr. Rini’s primary research has been in renal cell carcinoma (RCC), with special focus on antiangiogenic therapy and immunotherapy. Dr. Rini’s research has been published in peer-reviewed journals that include the New England Journal of Medicine, Journal of the National Cancer Institute, Journal of Clinical Oncology, Lancet and the Journal of the American Medical Association.
Certified in Medical Oncology by the American Board of Internal Medicine, Dr. Rini is active in numerous professional organizations, including ASCO, the Society for Immunotherapy of Cancer and is a member of the Oncologic Drugs Advisory Committee (ODAC).
Disclosures: In the past two years, Dr. Rini has served as a consultant or advisor to and/or has received research funding from Bristol-Myers Squibb, Merck, Pfizer, Novartis, and AstraZeneca/MedImmune.
Last Updated: August 2018